Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026
Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026
Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026
Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026
Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Policy / Regulatory

NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023

Fineline Cube Jul 26, 2024

The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...

Company Deals R&D

CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine

Fineline Cube Jul 26, 2024

CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic...

Company Deals

Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations

Fineline Cube Jul 26, 2024

Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of...

Company Deals

Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology

Fineline Cube Jul 26, 2024

Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED,...

Company Deals

Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development

Fineline Cube Jul 26, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...

Company Deals

United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology

Fineline Cube Jul 26, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced...

Company Drug

Sinqi Pharmaceutical Gets NMPA Green Light for SQ-22031 Eye Drops to Treat Dry Eye Syndrome and Neurotrophic Keratitis

Fineline Cube Jul 26, 2024

Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received...

Company Medical Device

Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology

Fineline Cube Jul 26, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based...

Company Medical Device

Amoy Diagnostics’ APACE Receives Japanese Approval as Companion Diagnostic for MET-Inhibiting Therapies

Fineline Cube Jul 26, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a Chinese diagnostics company, has announced that it...

Company Drug

China’s NMPA Gives Tacit Nod to IASO Biotechnology’s IASO-782 for SLE Clinical Trials

Fineline Cube Jul 26, 2024

IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...

Company Drug

Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302

Fineline Cube Jul 26, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...

Company

AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges

Fineline Cube Jul 26, 2024

AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...

Company

Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales

Fineline Cube Jul 26, 2024

Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported...

Company

AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines

Fineline Cube Jul 26, 2024

AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...

Company Deals Drug

Amoytop Biotech Opts for NASH Drug Candidate KN069 in Licensing Deal with Alphamab Oncology

Fineline Cube Jul 26, 2024

Xiamen Amoytop Biotech Co., Ltd (SHA: 688278), a biopharmaceutical company based in China, has exercised...

Company Deals

Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China

Fineline Cube Jul 25, 2024

Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal...

Company

Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions

Fineline Cube Jul 25, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...

Company Deals

Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China

Fineline Cube Jul 25, 2024

Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets,...

Company Deals

Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion

Fineline Cube Jul 25, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group...

Company Drug

Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA

Fineline Cube Jul 25, 2024

Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...

Posts pagination

1 … 349 350 351 … 691

Recent updates

  • China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development
  • Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
  • Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
  • Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
  • CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.